Berberine

Generic Name: Berberine

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₁₈NO_₄

CAS Number: 2086-83-1

Unique Ingredient Identifier: 0I8Y3P32UF

Background: An alkaloid from Hydrastis canadensis L., Berberidaceae. It is also found in many other plants. It is relatively toxic parenterally, but has been used orally for various parasitic and fungal infections and as antidiarrheal.

Indication: 主要用于志贺菌属、霍乱弧菌等敏感病原菌所致的胃肠炎、细菌性痢疾等肠道感染。

外用用于治疗敏感细菌引起的宫颈糜烂。

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Berberine Effect on Cytokine, CRP, Metabolic Disturbance as an Adjunctive Therapy in Schizophrenia Patients

Not Applicable

Completed

Conditions: Schizophrenia

Interventions: Drug: Placebo
Drug: Berberine

First Posted Date: 2016-10-18

Last Posted Date: 2018-05-17

Lead Sponsor: Tianjin Anding Hospital

Target Recruit Count: 100

Registration Number: NCT02936414

Locations: 🇨🇳
Tianjin Anding Hospital, Tianjin, Tianjin, China

Berberine Prevent Contrast-induced Nephropathy in Patients With Diabetes

Phase 4

Completed

Conditions: Diabetes Mellitus
Chronic Kidney Disease

Interventions: Drug: Berberine

First Posted Date: 2016-06-21

Last Posted Date: 2022-03-29

Lead Sponsor: Nanjing First Hospital, Nanjing Medical University

Target Recruit Count: 800

Registration Number: NCT02808351

Locations: 🇨🇳
Nanjing First Hospital, Nanjing, Jiangsu, China

Helicobacter Pylori Eradication With Berberine Quadruple Therapy Versus Clarithromycin Quadruple Therapy

Phase 4

Completed

Conditions: Gastritis
Peptic Ulcer
Dyspepsia

Interventions: Drug: Berberine
Drug: clarithromycin
Drug: Bismuth
Drug: Lansoprazole
Drug: amoxicillin

First Posted Date: 2015-12-17

Last Posted Date: 2017-01-18

Lead Sponsor: Xijing Hospital of Digestive Diseases

Target Recruit Count: 566

Registration Number: NCT02633930

Locations: 🇨🇳
Xijing Hospital of Digestive Diseases, Xi'an, Shanxi, China
🇨🇳
Xijing Hospital of Digestive Disease, Xi'an, Shanxi, China

Bezafibrate Plus Berberine in Mixed Dyslipidemia

Phase 3

Completed

Conditions: Mixed Dyslipidemia

Interventions: Drug: Bezafibrate
Drug: Berberine plus Bezafibrate
Drug: Berberine

First Posted Date: 2015-09-14

Last Posted Date: 2023-02-24

Lead Sponsor: University of Guadalajara

Target Recruit Count: 36

Registration Number: NCT02548832

Locations: 🇲🇽
Institute of Experimental and Clinical Therapeutics (INTEC), CUCS, University of Guadalajara, Guadalajara, Jalisco, Mexico

Helicobacter Pylori Eradication With Berberine Quadruple Therapy Versus Bismuth-containing Quadruple Therapy

Phase 4

Completed

Conditions: Dyspepsia
Peptic Ulcer
Gastritis

Interventions: Drug: Berberine
Drug: Bismuth
Drug: esomeprazole
Drug: amoxicillin
Drug: clarithromycin

First Posted Date: 2014-11-20

Last Posted Date: 2015-09-03

Lead Sponsor: Xijing Hospital of Digestive Diseases

Target Recruit Count: 612

Registration Number: NCT02296021

Locations: 🇨🇳
Xijing Hospital of Digestive Diseases, Xi'an, Shanxi, China

Effect of Berberine on Hormonal and Metabolic Features in Obese Women With Polycystic Ovary Syndrome (PCOS)

Not Applicable

Conditions: Polycystic Ovary Syndrome
Obesity

Interventions: Drug: Placebo
Drug: Berberine

First Posted Date: 2010-06-08

Last Posted Date: 2013-05-10

Lead Sponsor: Heilongjiang University of Chinese Medicine

Target Recruit Count: 120

Registration Number: NCT01138930

Locations: 🇨🇳
First Affliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China
🇨🇳
Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
🇨🇳
Forth Affiliated Hospital of Harbin Medcal University, Harbin, Heilongjiang, China

and more 1 locations

Polycystic Ovary Syndrome (PCOS): Effect Of Letrozole and Berberine

Not Applicable

Conditions: Polycystic Ovary Syndrome

Interventions: Drug: Letrozole -Berberine
Drug: Letrozole
Drug: Berberine

First Posted Date: 2010-05-04

Last Posted Date: 2013-05-20

Lead Sponsor: Heilongjiang University of Chinese Medicine

Target Recruit Count: 660

Registration Number: NCT01116167

Locations: 🇨🇳
Shanxi Hospital of Chinese Medicine, Taiyuan, Shanxi, China
🇨🇳
SuqianMaternal and Child Health Hospital, Suqian, Jiangsu, China
🇨🇳
Mudanjiang maternal and children hospital, Mudanjiang, Heilongjiang, China

and more 15 locations

Role of Pioglitazone and Berberine in Treatment of Non-Alcoholic Fatty Liver Disease

Phase 2

Completed

Conditions: Nonalcoholic Fatty Liver Disease

Interventions: Behavioral: Life style intervention
Drug: pioglitazone
Drug: berberine

First Posted Date: 2008-03-12

Last Posted Date: 2012-06-05

Lead Sponsor: Xin Gao

Target Recruit Count: 184

Registration Number: NCT00633282

Locations: 🇨🇳
Department of Endocrinology and Metabolism,Shanghai Clinical Center of Diabetes,Shanghai Institute of Diabetes,The sixth people's Hospital Affiliated to Shanghai Jiaotong University, Shanghai, Shanghai, China
🇨🇳
Endocrinology and Metabolism Department, Zhongshan Hospital, Fudan University,, Shanghai, Shanghai, China
🇨🇳
Department of Endocrinology and Metabolism,The Fifth People's Hospital，Fudan University, Shanghai, Shanghai, China